Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients.

BACKGROUND Mixed cryoglobulinemia (MC) is a systemic vasculitis secondary to circulating immune complex deposition in the small vessels. In the overwhelming majority of patients, hepatitis C virus (HCV) infection represents the triggering factor of the disease. MC is characterized by multiple organ involvement, mainly skin, liver, renal, peripheral nerves, and less frequently by widespread vasculitis and cancer. OBJECTIVES To investigate the demographic, clinical, serologic features, and survival in a large series of MC patients. METHODS The study included 231 MC patients recruited between 1972 and 2001 at the Rheumatology Unit of the University of Pisa. All patients underwent wide clinicoserologic and virologic assessment. Cumulative survival rates were computed by the Kaplan-Meier method; moreover, the prognostic relevance of the main variables was investigated by Cox model analysis. RESULTS In 92% of cases, the presence of HCV infection was demonstrated (anti-HCV antibody, 92%; HCV RNA, 90%), whereas hepatitis B virus (HBV) represented the possible causative agent in only 1.8% of patients (HBV DNA). Clinically, the MC syndrome followed a relatively benign clinical course in over 50% of cases, whereas a moderate-severe clinical course was observed in one third of patients whose prognosis was severely affected by renal and/or liver failure. In a limited, but significant, percentage (15%) of individuals, the disease was complicated by a malignancy, ie, B-cell lymphoma, and less frequently by hepatocellular carcinoma, or thyroid cancer. The survival study by the Kaplan-Meier method revealed a significantly lower cumulative 10th-year survival, calculated from time of diagnosis, in MC patients compared with expected death in the age- and sex-matched general population. Moreover, significantly lower survival rates were observed in males and in subjects with renal involvement. The multivariate analysis by the Cox proportional hazard regression model further supported the above findings: an increased mortality risk of 98% was observed for male gender (male/female hazard ratio, 1.978) and of 197% in patients with, compared with those without, renal involvement (hazard ratio, 2.967). At the end of the follow-up, 97 patients were deceased, and in 79 of 97 patients, the causes of death were ascertained: nephropathy (33%), malignancies (23%), liver involvement (13%), and diffuse vasculitis (13%) were the most frequent causes of death. CONCLUSIONS Careful patient monitoring is recommended for a timely diagnosis of life-threatening MC complications, mainly nephropathy, widespread vasculitis, and B-cell lymphoma or other malignancies.

[1]  D. Sansonno,et al.  Detection and distribution of hepatitis C virus-related proteins in lymph nodes of patients with type II mixed cryoglobulinemia and neoplastic or non-neoplastic lymphoproliferation. , 1996, Blood.

[2]  G. D'Amico,et al.  Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. , 1998, Kidney international.

[3]  D. Yeshurun,et al.  bcl‐2 and immunoglobulin gene rearrangement in patients with hepatitis C virus infection , 2001, British journal of haematology.

[4]  G. Pasero,et al.  Polymoyositis, lung fibrosis, and cranial neuropathy in a patient with hepatitis C virus infection , 1996 .

[5]  S. Bombardieri,et al.  Lung involvement in essential mixed cryoglobulinemia. , 1979, The American journal of medicine.

[6]  M. Cuccia,et al.  Haplotype HLA-B8-DR3 Confers Susceptibility to Hepatitis C Virus-Related Mixed Cryoglobulinemia , 1998 .

[7]  W. P. Dixon,et al.  BMPD statistical software manual , 1988 .

[8]  A. Weiner,et al.  Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution , 1992, Journal of virology.

[9]  G. Longombardo,et al.  Hepatitis C virus and mixed cryoglobulinaernia , 1993 .

[10]  G. Alarcón,et al.  Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases. , 1988, Arthritis and rheumatism.

[11]  J. Pawlotsky,et al.  Immunological disorders in C virus chronic active hepatitis: A prospective case‐control study , 1994, Hepatology.

[12]  G. Pasero,et al.  Mixed cryoglobulinemia as a possible preneoplastic disorder. , 1995, Arthritis and rheumatism.

[13]  Felicia A Tucci,et al.  The cryoglobulins: an overview , 2001, European journal of clinical investigation.

[14]  S. Bombardieri,et al.  Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. , 1995, QJM : monthly journal of the Association of Physicians.

[15]  S. Bombardieri,et al.  Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. , 1993, Blood.

[16]  S. Bombardieri,et al.  Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations. , 1992, The Journal of rheumatology.

[17]  B. Frangione,et al.  Mixed cryoglobulinemia cross-reactive idiotypes: implications for the relationship of MC to rheumatic and lymphoproliferative diseases. , 1991, Seminars in hematology.

[18]  M. García-Carrasco,et al.  Hepatitis C Virus Infection Mimicking Primary Sjögren Syndrome: A Clinical and Immunologic Description of 35 Cases , 2001, Medicine.

[19]  S. Bombardieri,et al.  Hepatitis C Virus Genotype Analysis in Patients with Type II Mixed Cryoglobulinemia , 1996, Annals of Internal Medicine.

[20]  M. Lovy,et al.  Hepatitis C infection presenting with rheumatic manifestations: a mimic of rheumatoid arthritis. , 1996, The Journal of rheumatology.

[21]  G. Pasero,et al.  Hepatitis C virus infection in non‐Hodgkin's B‐cell lymphoma complicating mixed cryoglobulinaemia , 1994, European journal of clinical investigation.

[22]  S. Vento,et al.  Does hepatitis C virus cause severe liver disease only in people who drink alcohol? , 2002, The Lancet. Infectious diseases.

[23]  A. Antonelli,et al.  Thyroid cancer in HCV-related mixed cryoglobulinemia patients. , 2002, Clinical and experimental rheumatology.

[24]  C. Francès,et al.  Cryoglobulinémie et hépatite C : aggravation de la neuropathie périphérique après prise d'interféron alpha , 1999 .

[25]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[26]  D. Sansonno,et al.  Hepatitis C virus‐related proteins in kidney tissue from hepatitis C virus‐infected patients with cryoglobulinemic membranoproliferative glomerulonephritis , 1997, Hepatology.

[27]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[28]  M. Houghton,et al.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. , 1989, Science.

[29]  B. Walker,et al.  Hepatitis C virus infection. , 2001, The New England journal of medicine.

[30]  Felicia A Tucci,et al.  Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. , 2003, Blood.

[31]  Y. Levo,et al.  Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. , 1980, The American journal of medicine.

[32]  P. Brandtzaeg,et al.  Clinical and laboratory studies , 1986 .

[33]  M. Manns,et al.  Hepatitis C virus chronic infection as a common cause of mixed cryoglobulinaemia and autoimmune liver disease , 1994, Journal of internal medicine.

[34]  J. Clauvel,et al.  Biologic and clinical significance of cryoglobulins. A report of 86 cases. , 1974, The American journal of medicine.

[35]  D. Vergani,et al.  Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity , 1991, The Lancet.

[36]  A. Mazzocca,et al.  T(14;18) translocation in chronic hepatitis C virus infection , 2000, Hepatology.

[37]  L. Castagnetta,et al.  Epidemiology, Risk Factors, and Natural History of Hepatocellular Carcinoma , 2002, Annals of the New York Academy of Sciences.

[38]  K. Ohta,et al.  Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. , 1992, The American review of respiratory disease.

[39]  L. Mouthon,et al.  Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia. , 2002, Rheumatology.

[40]  V. Agnello,et al.  Localization of hepatitis C virus in cutaneous vasculitic lesions in patients with type II cryoglobulinemia. , 1997, Arthritis and rheumatism.

[41]  V. Agnello,et al.  Hepatitis C virus infection in type II mixed cryoglobulinemia. , 1993, Arthritis and rheumatism.

[42]  G. Pasero,et al.  Interstitial lung fibrosis and rheumatic disorders in patients with hepatitis C virus infection. , 1997, British journal of rheumatology.

[43]  Edoardo Cervoni,et al.  Hepatitis C , 1998, The Lancet.

[44]  G. Pasero,et al.  Mixed cryoglobulinaemia: a cross-road between autoimmune and lymphoproliferative disorders , 1998, Lupus.

[45]  G. Pasero,et al.  Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. , 2010, Arthritis and rheumatism.

[46]  R. Misiani,et al.  Successful treatment of HCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin. , 1999 .

[47]  A. Perl,et al.  Clonal B cell expansions in patients with essential mixed cryoglobulinaemia. , 1989, Clinical and experimental immunology.

[48]  S. Pileri,et al.  Hepatitis C Virus, B-Cell Disorders, and Non-Hodgkin’s Lymphoma , 2000 .

[49]  C. Vitali Classification criteria for Sjögren’s syndrome , 2003, Annals of the rheumatic diseases.

[50]  C. Ferri,et al.  [Hepatitis C virus infection and arthritis. A clinico-serological investigation of arthritis in patients with or without cryoglobulinemic syndrome]. , 2011, Reumatismo.

[51]  D. Valla,et al.  Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. , 1994, Gastroenterology.

[52]  S. Korsmeyer Bcl-2: a repressor of lymphocyte death. , 1992, Immunology today.

[53]  S. Chopra,et al.  Hepatitis C: A Multifaceted Disease: Review of Extrahepatic Manifestations , 1995, Annals of Internal Medicine.

[54]  C. Bréchot,et al.  Infection of peripheral mononuclear blood cells by hepatitis C virus. , 1992, Journal of hepatology.

[55]  M. Meltzer,et al.  Cryoglobulinemia--a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. , 1966, The American journal of medicine.

[56]  G. Pasero,et al.  Blood viscosity and filtration abnormalities in mixed cryoglobulinemia patients. , 1990, Clinical and experimental rheumatology.

[57]  F. Izzo,et al.  Is hepatitis C virus infection associated with thyroid cancer? A case‐control study , 2000, International journal of cancer.

[58]  G. Litman,et al.  Atypical glycosylation of an IgG monoclonal cryoimmunoglobulin. , 1987, The Journal of biological chemistry.

[59]  F. Spertini,et al.  Cryoglobulinemia induced by monoclonal immunoglobulin G rheumatoid factors derived from autoimmune MRL/MpJ-lpr/lpr mice. , 1987, Journal of immunology.

[60]  S. Bombardieri,et al.  Hypercomplementaemia as a marker of the evolution from benign to malignant B cell proliferation in patients with type II mixed cryoglobulinaemia. , 1994, British journal of rheumatology.

[61]  C. Ferri,et al.  Erectile dysfunction and hepatitis C virus infection. , 2002, JAMA.

[62]  M. Mihatsch,et al.  Renal disease in essential mixed cryoglobulinaemia. Long-term follow-up of 44 patients. , 1981, The Quarterly journal of medicine.

[63]  S. Bombardieri,et al.  Low-antigen-content diet in the treatment of patients with mixed cryoglobulinemia. , 1989, The American journal of medicine.

[64]  D. Sansonno,et al.  The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy. , 2000, Seminars in liver disease.

[65]  J. Goedert Infectious Causes of Cancer , 2000, Infectious Disease.

[66]  S. Herrine Approach to the Patient with Chronic Hepatitis C Virus Infection , 2002, Annals of Internal Medicine.

[67]  M. Mihatsch,et al.  Renal Disease in Essential Mixed Cryoglobulinaemia , 1981 .

[68]  E. Tanzi,et al.  Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. , 1994, The New England journal of medicine.

[69]  M. Szklo,et al.  Prevalence of Type 2 Diabetes Mellitus among Persons with Hepatitis C Virus Infection in the United States , 2000, Annals of Internal Medicine.

[70]  G. Pasero,et al.  Hepatocellular carcinoma in mixed cryoglobulinemia patients. , 1996, Clinical and experimental rheumatology.

[71]  R J Falk,et al.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference. , 1994, Arthritis and rheumatism.

[72]  G. Pasero,et al.  Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection. , 1996, The Journal of rheumatology.

[73]  M. Stone,et al.  Studies on monoclonal antibodies. II. Immune complex (IgM-IgG) cryoglobulinemia: the mechanism of cryoprecipitation. , 1974, Journal of immunology.

[74]  R. Scorza,et al.  Central nervous system involvement in patients with HCV-related cryoglobulinemia. , 1998, The American journal of the medical sciences.

[75]  W. C. Miller,et al.  Cryoglobulinemia based on interaction between a gamma macroglobulin and 7S gamma globulin. , 1962, The American journal of medicine.

[76]  G. Antonelli,et al.  Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. , 1991, Blood.

[77]  D. Hochstrasser,et al.  Two-dimensional polyacrylamide gel electrophoresis analysis of cryoglobulins and identification of an IgM-associated peptide. , 1994, Journal of immunological methods.

[78]  F. Izzo,et al.  HCV and cancer: a case-control study in a high-endemic area. , 2001, Liver.

[79]  R. Fanin,et al.  Efficacy and safety of rituximab in type II mixed cryoglobulinemia. , 2003, Blood.

[80]  M. Memon,et al.  Hepatitis C: an epidemiological review , 2002, Journal of viral hepatitis.

[81]  A. Kaplan Apheresis for renal disease. , 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[82]  D. Yeshurun,et al.  Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. , 2000, The Journal of rheumatology.

[83]  P. Farci,et al.  Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome [Science 1989;244:359-362]. , 2002, Journal of hepatology.

[84]  S. Bombardieri,et al.  Autoantibodies from mixed cryoglobulinaemia patients bind glomerular antigens , 1994, Clinical and experimental immunology.

[85]  G. Pasero,et al.  Infection of Peripheral Blood Mononuclear Cells by Hepatitis C Virus in Mixed Cryoglobulinemia , 1993 .

[86]  R. Jonsson,et al.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group , 2002, Annals of the rheumatic diseases.

[87]  D. Pisetsky,et al.  Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation , 1990, The Journal of experimental medicine.

[88]  R. Mcmurray,et al.  Polymyositis, pulmonary fibrosis, and hepatitis C. , 1995, Arthritis and rheumatism.

[89]  G. Pasero,et al.  Cryoglobulins and immune complexes in essential mixed cryoglobulinemia , 1986, La Ricerca in clinica e in laboratorio.

[90]  S. Bombardieri,et al.  Treatment of the renal involvement in mixed cryoglobulinemia with prolonged plasma exchange. , 1986, Nephron.

[91]  S. Abrignani,et al.  Perspectives for a hepatitis C virus vaccine. , 1998, Clinical and diagnostic virology.

[92]  P. Caini,et al.  Prevalence of bcl-2 Rearrangement in Patients with Hepatitis C VirusRelated Mixed Cryoglobulinemia with or without B-Cell Lymphomas , 2002, Annals of Internal Medicine.

[93]  A. Scarpa,et al.  Clonality of B‐cells in portal lymphoid infiltrates of HCV‐infected livers , 1998, The Journal of pathology.

[94]  S. Pileri,et al.  Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. , 2000, Arthritis and rheumatism.

[95]  F. D. De Rosa,et al.  Interferon toxicity in hepatitis C virus-associated type II cryoglobulinemia. , 1998, Clinical and experimental rheumatology.

[96]  C. Mazzaro,et al.  Regression of monoclonal B‐cell expansion in patients affected by mixed cryoglobulinemia responsive to α‐interferon therapy , 1996, Cancer.

[97]  A. Antonelli,et al.  Thyroid cancer in patients with hepatitis C infection. , 1999, JAMA.

[98]  P. Gorevic,et al.  Evaluation of cryoglobulins. , 1999, Archives of pathology & laboratory medicine.

[99]  Elaine S. Jaffe,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[100]  S. Pileri,et al.  Essential mixed cryoglobulinemia, type II: a manifestation of a low-grade malignant lymphoma? Clinical-morphological study of 12 cases with special reference to immunohistochemical findings in liver frozen sections. , 1988, Acta haematologica.

[101]  G. Monti,et al.  Secondary and Essential Cryoglobulinemias , 1983 .

[102]  J. Salmerón,et al.  Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. , 1998, Archives of internal medicine.